C4 Therapeutics

C4 lays off 30% of staff in aftermath of BRD9 degrader discontinuation
Fierce Biotech
Wed, 01/10/24 - 09:35 am
C4 Therapeutics
cancer
layoffs
Merck offers up to $610M for one of C4’s protein degraders
Fierce Biotech
Tue, 12/12/23 - 11:07 am
Merck
C4 Therapeutics
protein degradation
AACR 2022 – A weekend of updates yields few winners
EP Vantage
Tue, 04/12/22 - 10:34 am
AACR
Bicycle Therapeutics
Rubius Therapeutics
C4 Therapeutics
Zentalis
Affimed
Seagen
Astellas
Roche ditches EGFR drug pact with C4 Therapeutics
Fierce Biotech
Fri, 11/13/20 - 12:47 pm
Roche
C4 Therapeutics
EGFR
C4's Andrew Hirsch blows up IPO to $182M, while oncolytic virus upstart nabs $87M offering
Endpoints
Sun, 10/4/20 - 12:13 am
C4 Therapeutics
Oncorus
IPOs
oncolytic viruses
C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic
Xconomy
Wed, 06/17/20 - 09:58 am
C4 Therapeutics
funding
small molecule drugs
Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2017
BioSpace
Tue, 03/5/19 - 10:05 am
Denali Therapeutics
C4 Therapeutics
Neon Therapeutics
Biogen stock trends up on neurology disease deals
Biopharma Dive
Tue, 01/8/19 - 11:38 pm
Biogen
C4 Therapeutics
Skyhawk Therapeutics
Pair of deals boosts Biogen’s early-stage CNS pipeline
Pharmaforum
Mon, 01/7/19 - 11:20 am
Biogen
CNS
Alzheimer's disease
MS
C4 Therapeutics
Skyhawk Therapeutics
Sleuthy Google upstart Calico forges a rare biotech collaboration on aging with Novartis-backed C4
Endpoints
Fri, 03/24/17 - 09:39 am
Google
Calico
biotech
C4 Therapeutics
Novartis